• Sugarbud Craft Growers (SUGR) has announced a share consolidation program, effective February 18, 2002
  • The company will be consolidating all of its issued and outstanding common shares on the basis of a ratio of one hundred pre-consolidation shares for one post-consolidation share
  • The share consolidation will not change current value or the per cent ownership each shareholder has in the company
  • Sugarbud is an Alberta-based, consumer-driven boutique craft cannabis company
  • Sugarbud Craft Growers Corp. (SUGR) opened trading at C$0.02 per share

Sugarbud Craft Growers (SUGR) has announced a share consolidation program.

The company will be consolidating all of its issued and outstanding common shares on the basis of a ratio of one hundred pre-consolidation shares for one post-consolidation share, effective February 18, 2022.

Following the consolidation, Sugarbud will have a total of 5,699,796 common shares in issue. The share consolidation will not change current value or the per cent ownership each shareholder has in the company.

The consolidated shares will trade from the morning of February 18, 2022 under the following ISIN and CUSIP codes: ISIN: CA8650013094, CUSIP: 865001309.

The number of outstanding common share purchase warrants, options, or other convertible securities will not be altered; however, the exercise prices and number of shares to be issued upon the exercise of any warrants, options, or other convertible securities will be proportionally adjusted on the basis of the 100:1 consolidation ratio.

Sugarbud is a craft cannabis company focused on the cultivation and production of superior, select-batch, craft cannabis products.

Sugarbud Craft Growers Corp. (SUGR) opened trading at C$0.02 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.